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Cardiac transplantation remains the only definitive
treatment for end-stage heart failure. Transplantation
rates are limited by a shortage of donor hearts. This
shortage is magnified because many hearts are dis-
carded because of strict selection criteria and con-
cern for regulatory reprimand for less-than-optimal
posttransplant outcomes. There is no standardized
approach to donor selection despite proposals to lib-
eralize acceptance criteria. A donor heart selection
conference was organized to facilitate discussion
and generate ideas for future research. The event
was attended by 66 participants from 41 centers
with considerable experience in cardiac donor selec-
tion. There were state-of-the-art presentations on
donor selection, with subsequent breakout sessions
on standardizing the process and increasing utiliza-
tion of donor hearts. Participants debated miscon-
ceptions and established agreement on donor and
recipient risk factors for donor selection and identi-
fied the components necessary for a future donor
risk score. Ideas for future initiatives include modifi-
cation of regulatory practices to consider extended
criteria donors when evaluating outcomes and
prospective studies aimed at identifying the factors
leading to nonacceptance of available donor hearts.
With agreement on the most important donor and
recipient risk factors, it is anticipated that a consis-
tent approach to donor selection will improve rates
of heart transplantation.
Abbreviations: CAV, cardiac allograft vasculopathy;
CPRA, calculated panel reactive antibody; CPR, car-
diopulmonary resuscitation; ECD, extended criteria
donor; ECMO, extracorporeal membrane oxygena-
tion; ISHLT, International Society of Heart and Lung
Transplantation; LVEF, left ventricular ejection frac-
tion; LVH, left ventricular hypertrophy; LV, left ven-
tricular; MCS, mechanical circulatory support; MFI,
mean fluorescence intensity; OPO, organ procure-
ment organization; PGD, primary graft dysfunction;
PTR, potential transplant recipient; RVAD, right ven-
tricular assist device; SRTR, Scientific Registry of
Transplant Recipients; UNOS, United Network for
Organ Sharing; VAD, ventricular assist device
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Introduction
A conference took place May 1, 2015, at the American
Transplant Congress in Philadelphia, Pennsylvania, to pro-
vide a forum for in-depth expert discussion regarding
donor management and donor heart selection for trans-
plantation. The conference, which was endorsed by the
American Society of Transplantation, was attended by 66
participants, many of whom had published on the topic
and possessed vast clinical experience in heart transplan-
tation (including cardiologists, cardiac surgeons, trans-
plant coordinators, and organ procurement professionals;
see Appendix A). Participants came from 41 heart trans-
plant centers across the United States.
Prior to the conference, opinions regarding current
donor selection and management practices were soli-
cited from transplant centers via an online survey. This
survey included questions about donor management
protocols, perceived donor and recipient risk factors,
selection criteria, and general clinical practice regarding
donor selection. Important survey results were noted:
Most respondents believe that oversized donors are
needed for recipients with pulmonary hypertension,
2559
© 2017 The American Society of Transplantation
and the American Society of Transplant Surgeons
doi: 10.1111/ajt.14354
American Journal of Transplantation 2017; 17: 2559–2566
Wiley Periodicals Inc.
place most importance on height for donor matching,
and view undersizing a same-sex donor heart to recipi-
ent by >30% as a contraindication. The most common
criteria that would cause a donor heart to be turned
down include left ventricular (LV) ejection fraction
≤50%, cold ischemia time >4 h, left ventricular hypertro-
phy (LVH) >1.3 cm, and donor age >55 years. All
responses received from 47 transplant centers (more
centers responded to the survey than attended the
meeting) are summarized in Table 1.
Donor heart selection is currently based on several factors
including echocardiographic parameters, hemodynamics,
catheterization results, pressor requirements, intraopera-
tive anatomic considerations, multiorgan procurement,
and postprocurement function (as in ex vivo perfusion).
Table 1: Results of preconference online survey: 47 centers participating (survey conducted January 2015–April 2015)
Survey respondent demographics:
• 47 different heart transplant centers represented
• 11 UNOS regions represented roughly equally
• Distribution between small (1–19/year), medium (20–39/year), and large (≥40/year) centers in transplant volume (36%, 38%, and
23%, respectively)
• Distribution between small (1–19/year), medium (20–39/year) and large (≥40/year) centers in MCS implant volume (9%, 36%, and
53%, respectively)
On the issue of sizing donor/recipient
• 58% believed that oversized donors are needed for recipients with pulmonary hypertension, 42% disagree
• Among those who use oversize donors in this scenario, 46% prefer to oversize 10% by body weight, and 54% prefer to oversize
20% by body weight
• 57% of respondents place most importance on height in donor-to-recipient ratio, whereas 43% place most importance on weight
• 69% of respondents view undersizing a same-sex donor heart to recipient by >30% as a contraindication to heart transplant; 31%
do not view it as such
• 30% of respondents view oversizing a same-sex donor heart to recipient by >30% as a contraindication to heart transplant; 70%
do not view it as such
• For female donor heart to male recipient, 46% would oversize the donor, 48% believe no oversizing is necessary, and 6% would
accept an undersized heart
On risk factors and their importance
• Asked to rank donor risk factors in order of their perceived importance, the five most important were heart function (LVEF), pres-
ence of LV wall motion abnormality, presence of hypertrophy, cold ischemic time, and donor age
• Asked what level of LVH would cause them to reject a heart, assuming no other mitigating circumstances, 21% chose >1.2 cm,
45% chose >1.3 cm, 21% chose >1.4 cm and 13% chose >1.5 cm
• Asked what expected ischemia time would cause them to reject a heart, assuming no other mitigating circumstances, 34% said
>4 h, 34% said >5 h, 30% said >6 h and 2% said >7 h
• Asked what LVEF level would cause them to reject a heart, assuming no other mitigating circumstances, 21% said ≤40%, 30%
said ≤45%, and 49% said ≤50%
• Asked what an unacceptable downtime (administration of CPR duration) would be for acceptance of a donor heart, 20% said
>20 min, 38% said >30 min, 23% said >40 min, and 20% said >60 min
• Asked to determine the threshold for acceptable right atrial pressure (after donor optimization) to proceed to transplantation, 30%
said <10 mmHg, 59% said <15 mmHg, and 11% said <20 mmHg
• 34% of respondents require donor hearts to be off inotropes to proceed to transplant, 66% do not require this
• Asked to specify the level of dependence on inotropes that would still result in acceptance of a donor heart, 15% specified “no
inotropes,” 34% specified a “minimal level of inotropes,” 47% specified a “mild level of inotropes,” and 4% specified a “moder-
ate level of inotropes”
• Asked to specify an upper donor age limit that respondents would consider accepting, 2% said age 45, 23% said age 50, 42%
said age 55, 19% said age 60, 9% said age 65, 2% said age 69, and 2% said age 70
• Asked to specify the acceptable age differential threshold for transplanting older donors into younger recipients, 33% said
>10 years, 50% said >20 years, 13% said >30 years, and 4% said >40 years
• 38% of respondents routinely use older donors (>50 years) for older recipients (>60 years) at their program; 62% do not
• Asked to rank recipient risk factors in order of their perceived importance, the five most important were high sensitization level,
presence of complications associated with VAD, presence of temporary circulatory support, mechanical ventilation before trans-
plant, and congenital heart disease
On donor management strategies
• 53% of respondents normally request the use of thyroid hormone to optimize donor heart function; 47% do not
• 22% of respondents normally request the use of corticosteroids to optimize donor heart function; 78% do not
CPR, cardiopulmonary resuscitation; LV, left ventricular; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; MCS,
mechanical circulatory support; UNOS, United Network for Organ Sharing; VAD, ventricular assist device.
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Nevertheless, no standardized approach exists for man-
agement and weighing of donor and recipient risk factors,
resulting in considerable variability between transplant
centers in clinical practice. As a result, between-center
comparisons and research collaborations have been diffi-
cult to implement. The purpose of this conference was to
initiate the process of standardization of donor selection
for heart transplantation, to optimize overall outcomes,
and to enable future collaborative research.
Current Understanding of Donor Heart
Selection
Donor risk factors: What is important?
Donor characteristics influence posttransplant outcomes,
but there is contention as to the degree of risk that many
of these factors represent. Traditionally, the prevailing
opinion (supported by International Society of Heart and
Lung Transplantation [ISHLT] registry data (1)) has been
that increasing donor age is a risk factor for mortality
after cardiac transplantation. The median donor age for
utilized hearts is currently 35 years in the United States
(1) and 43 years in Europe (2). The combination of older
donor and older recipient portends a higher risk of mor-
tality and development of cardiac allograft vasculopathy
(CAV) (1). In addition, use of hearts from older donors for
critically ill status 1A candidates results in higher mortal-
ity than use of younger donor hearts, but posttransplant
survival remains better than if these patients were not to
receive a transplant. Two recent European retrospective
studies demonstrated similar survival outcomes between
recipients of younger and older donor hearts but
increased risk of CAV in recipients of the older hearts
(3,4).
The issue of LVH in donor selection is controversial with
no clear accepted boundaries on acceptable level of wall
thickness. Although a single-center study at Stanford
found LV wall thickness of >1.4 cm to be significantly
associated with reduced survival (5), others have found
that mild and moderate LVH (up to 1.7 cm) has no
adverse effect on survival (6). A subsequent analysis of
United Network for Organ Sharing (UNOS) data showed
no difference in survival between groups with no LVH,
mild LVH (1.1–1.3 cm), and moderate to severe LVH
(≥1.4 cm) (7). However, the combination of older age
(>55 years) and the presence of LVH, as well as
ischemic time >4 h in the presence of LVH, was found
to negatively affect survival (7).
Examination of interactions between factors may pro-
vide important insights that explain some of the conflict-
ing results from studies describing individual risk
factors. Multiple studies reveal increasing donor age as
a predictor of mortality, but the combination of older
age and longer ischemic time, as well as age and gen-
der mismatch (female to male), appears particularly
detrimental to long-term outcomes. A multi-institutional
study by Stehlik et al (8) used multivariable logistic
regression analysis to identify donor-associated risk pre-
dictors and important interactions between these donor
characteristics. The study found that a history of hyper-
tension and diabetes mellitus were risk factors for early
recipient mortality in male donors but not in female
donors. There was also a significant interaction between
donor age and donor–recipient weight difference, with
increased risk of death in those with increasing weight
difference (undersized donor heart). Donor and recipient
gender further modified the degree of risk, with a
higher risk with female donors when recipients were
male.
As a result of these observations, the use of a validated
donor risk score taking these interactions into account
may provide the best risk prediction in the future. Two
studies, Smits et al (9) using a European database and
Weiss et al (10) using the UNOS database, designed and
validated donor heart scores that accurately reflected the
likelihood of donor heart acceptance and predicted long-
term patient mortality. A major criticism of both studies
is that recipients supported with mechanical circulatory
support (MCS) were not included in their models. A
recent study by Johnston et al (11) used a transplant risk
score specifically for patients on MCS. A 75-point scoring
system encompassing nine recipient and four donor vari-
ables was used to predict the 1-year mortality of patients
on MCS if they were to undergo transplantation. The
study found that several variables, such as renal function,
recipient age, recent infection, total bilirubin, and preop-
erative ventilatory support, are consistent with non-MCS
patient risk factors. Variables unique to patients on MCS
include BMI, intensive care admission, and MCS type.
Such a risk score may be useful for determining organ
allocation in patients on MCS but requires further valida-
tion.
Recipient risk factors in the context of donor heart
selection
Like donor risk factors, recipient factors in donor selec-
tion need to be considered. Traditionally, the following
recipient factors have influenced donor heart selection:
age of the patient, size/weight ratio, pulmonary vascular
resistance, presence and/or type of circulatory support,
and antibody sensitization. In every case, these factors
are considered relative to the prospective donor.
The presence of pretransplant renal dysfunction in the
recipient has been reported as a risk factor. ISHLT reg-
istry data demonstrate increased posttransplant 5- and
10-year mortality in recipients with increased pretrans-
plant creatinine (1).
Additional factors resulting in a high-risk recipient are
presence of a total artificial heart, biventricular/right ven-
tricular assist device, those on temporary circulatory
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support or ventilator prior to transplant, and those with a
recent history of dialysis (1).
Balancing donor and recipient risk in donor selection
Individual donor and recipient risk factors do not deter-
mine posttransplant outcome. It is the complex interac-
tions among risk factors that play a critical role in the
outcome of heart transplantation.
Donor/recipient gender mismatch is of great interest
since an ISHLT registry study showed that male recipi-
ents of female donor hearts had the lowest 5-year actu-
arial survival and the highest risk of CAV, whereas 5-
year actuarial survival in female recipients was not
affected by donor gender (12). Interestingly, a study
that combined gender and age found that donor gender
had no effect on survival in female or male recipients
<45 years of age but that female donors conferred a
higher risk of mortality to male recipients who were
>45 years old (13).
Regarding donor/recipient matching, oversizing of donors
for recipients with pulmonary hypertension is controver-
sial. An analysis of UNOS data involving 15 284 trans-
plants revealed no significant effect of smaller weight
ratio (<0.8) on the risk of short- or long-term mortality
after transplantation (14); however, recipients with ele-
vated pulmonary vascular resistance who received under-
sized hearts had worse survival. Furthermore, in the
setting of high pulmonary vascular resistance, male recip-
ients who received hearts from female donors had
worse survival than those who received hearts from
male donors. A retrospective cohort study of 31 634
patients from the UNOS registry found that donor weight
alone did not predict recipient posttransplant survival;
instead, predicted total donor heart mass was a better
discriminator (15). In that study, a mismatch >10–15%
below the recipient’s predicted donor heart mass was
associated with reduced survival.
Intraoperative risk factors
Many intraoperative risk factors relate to donor manage-
ment prior to implantation in the recipient including
ischemic time, reperfusion, cardioplegia solution, and
whether an MCS device is present. These intraoperative
risk factors may increase the risk of primary graft dys-
function (PGD), which remains a significant cause of
posttransplant morbidity and mortality, as it is associated
with up to two-thirds of deaths in the first 30 days after
transplant.
Another intraoperative risk factor that has been linked
with posttransplant outcome is the presence of an MCS
device at the time of transplantation. Patients bridged to
transplant with MCS also require increased cardiopul-
monary bypass time and increased inotrope use, which
are known risk factors for adverse postoperative
outcomes (16). In addition, more blood products for a
coagulopathy are generally required in these patients,
and there is an increased risk of vasoplegia. With
increased blood products, the right ventricle of the donor
heart may dilate and fail; therefore, many programs may
desire a younger donor heart that can accommodate
right ventricular stress.
Other specialty considerations
Immunologic risk factors: avoiding hyperacute
rejection: Although overall rejection rates have declined
substantially over the years with the advent of more
effective immunosuppression, almost 5% of patients still
experience either cellular or antibody-mediated rejection
within the first 30 days of transplant. Hyperacute
rejection, although infrequent, remains a concern because
of its devastating consequences (17). Pretransplant
sensitization is a major risk factor for early rejection. With
the emergence of MCS as an effective bridge to
transplantation, the number of sensitized patients
awaiting heart transplant is on the rise, with a third of
patients now demonstrating positive panel reactive
antibodies at transplant (17). The challenge for these
patients is that sensitization limits the donor pool (due to
incompatible donors), prolongs time on the waitlist, and
increases waitlist mortality. After transplantation,
increased rejection may lead to graft loss or development
of allograft vasculopathy (18–20).
Extended criteria donor hearts: standardizing
definitions and criteria for use: The extended criteria
donor (ECD) heart, although lacking a unified formal
definition, has traditionally been defined by several risk
factors. These risk factors include one or more of the
following: donor age >40 years; a history of chest trauma;
prolonged hospitalization; prolonged cardiopulmary
resuscitation or downtime; a history of diabetes, tobacco,
or illicit drug use; transient reversible hypotension; short-
term, high-dose catecholamine administration; and a
substantially smaller weight donor compared with the
recipient. In 2001, a consensus-led donor management
algorithm specifying suitable hemodynamic and
echocardiographic parameters for donor hearts was
devised and incorporated into the UNOS critical pathway
(21).
Considerable evidence shows that ECD hearts that may
result in favorable posttransplant survival continue to be
discarded. A retrospective review of 1872 potential organ
donors in California from 2001 to 2008 showed predic-
tors of nonuse to be age >50 years, female sex, death
attributable to cerebrovascular accident, hypertension,
diabetes mellitus, a positive troponin assay, LV dysfunc-
tion (LV ejection fraction <50%), regional wall motion
abnormalities, and LVH (21). These characteristics, how-
ever, seemed to have little effect on recipient outcomes
when some of these hearts were transplanted.
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Breakout Sessions From the Donor
Selection Conference
Each breakout session group included a balanced mix of
cardiologists, cardiac surgeons, pathologists, transplant
coordinators, and organ procurement professionals. All
points of consensus, as well as notable points of con-
tention, were recorded and presented to a reconvened
session of all conference participants.
Discussions took place under four main themes:
1 Identifying best practices regarding donor selection
and management
2 Consideration of risk in donor selection
3 Donor scoring system: what to include
4 Areas for further study
Theme 1: Identifying best practices regarding donor
selection and management
There was considerable discussion on common practices
in donor heart selection. These practices include the use
of oversized donor hearts for pulmonary hypertension,
female donor to male recipient, duration of resuscitation
and amount of inotropic support offset by normal cardiac
function, and the use of a young male donor that out-
weighs all other risk factors for donor acceptance in
most scenarios. These and other key points from this
discussion are summarized in Table 2.
Theme 2: Consideration of risk in donor selection
Donor and recipient risk factors: Donor age was
universally viewed as the most important risk factor to
consider in a heart offer, along with LV function (defined
as ejection fraction <50% that failed to improve after
donor resuscitation) and the presence of LVH. The
distance from a transplant center was also considered to
be very important because longer distances would
increase the cold ischemic time, which is associated
with poorer outcomes after transplantation (22).
For most participants, recipient age was again one of the
most important risk factors to consider, given the worse
outcomes demonstrated in recipients aged >60 years
(16). Other high-priority recipient risk factors included the
presence of pulmonary hypertension, congenital heart
disease, and/or MCS, as well as redo heart transplanta-
tion. Some participants also felt that the severity of end-
organ dysfunction in the recipient (i.e. serum bilirubin,
creatinine) and whether the patient was on mechanical
ventilation before transplant should also be considered
as high risk. Amyloid patients were also an area of con-
tention because debate is ongoing about whether light-
chain amyloid patients should be transplanted, given the
systemic nature of the disease.
It was agreed that these prioritizations of both donor and
recipient risk factors were necessary for standardizing
the approach to donor selection and that these discus-
sions would be referred to the Scientific Registry of
Transplant Recipients in the hope of contributing toward
a donor selection risk score that incorporates these fac-
tors and helps increase donor acceptance rates. A sum-
mary of donor and recipient risk factors and their level of
importance can be found in Table 3.
Regulatory oversight in donor selection: There was
concern regarding the issue of regulatory oversight and
how it affects donor selection. As Khush et al demons-
trated in a recent paper, there has been a decrease over
the past 20 years in the use of available donor hearts (12).
This may be related to increased scrutiny of posttransplant
outcomes by national regulatory bodies (i.e. UNOS
Membership Professional Standards Committee). If there
is a reduced observed/expected survival ratio, a transplant
center may be warned or reprimanded, placed on
probation, or even closed. In addition, this could result in
loss of Medicare certification and could adversely affect a
transplant center’s contracts with medical insurance.
The group was concerned that the statistical models
used for risk adjustment may not fully adjust for all donor
and recipient characteristics (e.g. highly sensitized
patient, different forms of MCS, preexisting coronary
artery disease). Centers that perform a disproportionate
number of high-risk transplants may be penalized unfairly
for “low” performance. Consequently, there is a disin-
centive for centers to transplant riskier donors or recipi-
ents, especially at smaller centers where survival ratios
Table 2: Key points for donor selection: debunking myths
• Oversizing is not necessarily needed for recipients with pulmonary hypertension, but undersizing should be avoided (23)
• Oversizing is not necessarily needed for female donors to male recipients and should be assessed on case-by-case basis (13,15)
• LV mass index should be considered in conjunction with height and weight (5–7)
• Younger donor age and good graft function should be prioritized above all other risk factors (1,3,4)
• There is no unacceptable length of CPR (“downtime”) if echocardiographic function of the donor heart and other donor factors are
favorable (21)
• Use of low-dose inotrope and vasopressors on the donor heart is acceptable to proceed to transplant; use of norepinephrine,
epinephrine, and/or multiple inotropes should be viewed with caution (24)
CPR, cardiopulmonary resuscitation; LV, left ventricular.
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can be greatly affected by just one or two deaths. Partici-
pants at this forum strongly felt that more data (for these
unmeasured characteristics, e.g. sensitization level, MCS
use) should be incorporated into the risk adjustment
models. There could be additional incentives for using
higher risk donors to counteract the conservative
approach that results in high discard rates.
Theme 3: Working toward a useful donor risk score
The donor heart selection process of matching the donor
heart to the ideal recipient involves meticulous review of
both donor and recipient characteristics and considera-
tion of factors such as ischemic time and problems in
special recipient populations, such as the risk of bleeding
and prolonged operations in candidates with durable
MCS devices. There was agreement that a donor-selec-
tion risk scoring system would be an extremely useful
tool that would provide a standardized approach to the
practice of donor selection.
Participants agreed that for such a score to be practical,
it would have to be calculated in real time and displayed
in UNet/DonorNet, the U.S. organ allocation platform. A
potential issue was the continually evolving use of MCS
devices and improving survival in waitlist patients; there-
fore, such a score would have to be continually updated
with new data.
In addition to donor and recipient factors, a donor risk
score might include waitlist mortality, risk of PGD, post-
transplant mortality (30 days, 1 and 3 years), and longer
term outcomes such as incidence of CAV. Waitlist mor-
tality and the relative risk of not taking the heart were
also felt to be important to assess the relative benefit of
transplantation, but the majority felt that the score
should be weighted toward the risks of donor use over
the relative risk of donor nonuse. In addition, projected
quality of life after transplant was proposed as a factor,
but the majority felt that it was too difficult to
incorporate. Everyone agreed that prospective validation
of the score would have to occur based on observed out-
comes. In implementing its use, it was agreed that deci-
sion guidelines based on score ranges would be needed.
The score would also be valuable in clarifying criteria for
ECDs based on the quantified expected risk associated
with the donor characteristics.
There were regulatory concerns regarding the implemen-
tation of the score: There was a fear that transplant cen-
ters with higher risk scores might be penalized. Some
participants suggested excluding high-risk transplants
from outcome measures or allowing a percentage of
high-risk transplants. A scoring system has great poten-
tial to become a vital tool for providing a standardized
approach to the practice of donor selection while poten-
tially reducing the number of hearts discarded.
Theme 4: Suggestions for further action and studies
in donor selection
Further action and research revolve around more refined
donor heart functional studies, factors leading to donor
heart nonuse, utilization of donor biomarkers of outcome,
donor management, and optimal strategies for the use of
ECD hearts. These further actions are summarized in
Table 4.
Summary of Donor Heart Selection
Conference
The increasing success of cardiac transplantation as a
treatment for heart failure is currently mitigated by the
relative unavailability of donor organs, limiting transplan-
tation rates. Despite a long waitlist, a high percentage of
donor hearts are discarded due to strict yet nonstandard-
ized selection criteria. This donor heart selection confer-
ence was an attempt to discuss the current process of
donor selection, with the eventual aim of standardizing
Table 3: Risk factors to be considered in donor selection, by tier of importance
Donor risk factors Recipient risk factors
Most important Most important
Older age
Left ventricular function
Presence of LVH
Cold ischemic time/distance from transplanting center
High inotrope use
Older age
Congenital heart disease as etiology of heart failure
Severe organ dysfunction (as reflected by elevated creatinine or
total bilirubin)
Pulmonary hypertension
Temporary circulatory support (RVAD, Impella, ECMO), especially if
complicated
Mechanical ventilation
Amyloid
Important Important
Sex mismatch (female to male)
Preexisting coronary artery disease
Malignancy as cause of death
Redo heart transplant
Sensitization level of patient
ECMO, extracorporeal membrane oxygenation; LVH, left ventricular hypertrophy; RVAD, right ventricular assist device.
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the process across transplant centers and increasing uti-
lization of available donor hearts. Through discussion, the
participants debunked common misconceptions, estab-
lished an agreement on a practical approach to the most
important donor and recipient risk factors during donor
selection, and identified the components necessary for a
future donor selection risk score. Furthermore, the group
raised ideas for future work, including modifying regula-
tory practices to include consideration of high-risk donors
and candidates when evaluating transplant center out-
comes, and future prospective studies to identify the fac-
tors behind donor heart nonuse.
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